IL295236A - Methods of treating and preventing engraftment arrhythmias - Google Patents
Methods of treating and preventing engraftment arrhythmiasInfo
- Publication number
- IL295236A IL295236A IL295236A IL29523622A IL295236A IL 295236 A IL295236 A IL 295236A IL 295236 A IL295236 A IL 295236A IL 29523622 A IL29523622 A IL 29523622A IL 295236 A IL295236 A IL 295236A
- Authority
- IL
- Israel
- Prior art keywords
- administration
- amiodarone
- ivabradine
- cardiomyocytes
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 175
- 206010003119 arrhythmia Diseases 0.000 title claims description 161
- 230000006793 arrhythmia Effects 0.000 title claims description 144
- 238000011282 treatment Methods 0.000 title description 135
- 230000002265 prevention Effects 0.000 title description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 197
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 claims description 195
- 229960005260 amiodarone Drugs 0.000 claims description 193
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 claims description 180
- 229960003825 ivabradine Drugs 0.000 claims description 180
- 210000004027 cell Anatomy 0.000 claims description 130
- 230000000747 cardiac effect Effects 0.000 claims description 87
- 241000282414 Homo sapiens Species 0.000 claims description 63
- 238000001990 intravenous administration Methods 0.000 claims description 41
- 210000000130 stem cell Anatomy 0.000 claims description 37
- 208000010125 myocardial infarction Diseases 0.000 claims description 35
- 208000001871 Tachycardia Diseases 0.000 claims description 34
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 33
- 230000006794 tachycardia Effects 0.000 claims description 31
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 28
- 238000000338 in vitro Methods 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 19
- 210000002966 serum Anatomy 0.000 claims description 15
- 208000019622 heart disease Diseases 0.000 claims description 14
- 230000000284 resting effect Effects 0.000 claims description 14
- 208000035999 Recurrence Diseases 0.000 claims description 10
- 210000005003 heart tissue Anatomy 0.000 claims description 9
- 208000028867 ischemia Diseases 0.000 claims description 7
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 5
- 230000036262 stenosis Effects 0.000 claims description 5
- 208000037804 stenosis Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 4
- 206010067171 Regurgitation Diseases 0.000 claims description 4
- 230000003143 atherosclerotic effect Effects 0.000 claims description 4
- 206010061592 cardiac fibrillation Diseases 0.000 claims description 4
- 208000028831 congenital heart disease Diseases 0.000 claims description 4
- 230000002600 fibrillogenic effect Effects 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 claims description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 69
- 241001465754 Metazoa Species 0.000 description 41
- 238000002054 transplantation Methods 0.000 description 37
- 230000003288 anthiarrhythmic effect Effects 0.000 description 34
- 230000000694 effects Effects 0.000 description 32
- 239000003814 drug Substances 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 230000033764 rhythmic process Effects 0.000 description 28
- 230000004083 survival effect Effects 0.000 description 28
- 206010019280 Heart failures Diseases 0.000 description 27
- 241000282887 Suidae Species 0.000 description 26
- 229940079593 drug Drugs 0.000 description 26
- 238000002560 therapeutic procedure Methods 0.000 description 25
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 23
- 241000282898 Sus scrofa Species 0.000 description 22
- 206010061216 Infarction Diseases 0.000 description 21
- 230000008672 reprogramming Effects 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 18
- 230000007574 infarction Effects 0.000 description 18
- 230000035800 maturation Effects 0.000 description 18
- 210000003742 purkinje fiber Anatomy 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 210000004165 myocardium Anatomy 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 208000003663 ventricular fibrillation Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 210000001082 somatic cell Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 238000002565 electrocardiography Methods 0.000 description 12
- 210000001778 pluripotent stem cell Anatomy 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 206010049993 Cardiac death Diseases 0.000 description 10
- 206010011906 Death Diseases 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 231100000517 death Toxicity 0.000 description 10
- 230000002459 sustained effect Effects 0.000 description 10
- 230000001052 transient effect Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 206010015548 Euthanasia Diseases 0.000 description 8
- 210000004504 adult stem cell Anatomy 0.000 description 8
- 238000013194 cardioversion Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 7
- 206010062016 Immunosuppression Diseases 0.000 description 7
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 7
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 7
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 7
- 241001485053 Suid betaherpesvirus 2 Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 201000000317 pneumocystosis Diseases 0.000 description 7
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 7
- 101710177922 Gap junction alpha-5 protein Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000009256 replacement therapy Methods 0.000 description 6
- 208000020446 Cardiac disease Diseases 0.000 description 5
- 102000013814 Wnt Human genes 0.000 description 5
- 108050003627 Wnt Proteins 0.000 description 5
- 230000002763 arrhythmic effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 108010014510 connexin 40 Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000002064 heart cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 229960004194 lidocaine Drugs 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 4
- 102000004257 Potassium Channel Human genes 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 229960000449 flecainide Drugs 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229960002237 metoprolol Drugs 0.000 description 4
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 4
- 244000309715 mini pig Species 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108020001213 potassium channel Proteins 0.000 description 4
- 229960000203 propafenone Drugs 0.000 description 4
- 229960002370 sotalol Drugs 0.000 description 4
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- -1 1 day Chemical compound 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 208000013875 Heart injury Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000003976 gap junction Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 229940126121 sodium channel inhibitor Drugs 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229930185603 trichostatin Natural products 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- 208000001193 Accelerated Idioventricular Rhythm Diseases 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000764260 Homo sapiens Troponin T, cardiac muscle Proteins 0.000 description 2
- 108010048829 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Proteins 0.000 description 2
- 102000009453 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Human genes 0.000 description 2
- 244000141359 Malus pumila Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 2
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 230000001269 cardiogenic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940125400 channel inhibitor Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 208000037891 myocardial injury Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000000449 purkinje cell Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HPTXLHAHLXOAKV-INIZCTEOSA-N (2S)-2-(1,3-dioxo-2-isoindolyl)-3-(1H-indol-3-yl)propanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 HPTXLHAHLXOAKV-INIZCTEOSA-N 0.000 description 1
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- GEBBCNXOYOVGQS-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](NO)O1 GEBBCNXOYOVGQS-BNHYGAARSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150020912 CACNA2D2 gene Proteins 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000006630 Contactin 2 Human genes 0.000 description 1
- 108010087196 Contactin 2 Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 235000019754 Grower Diet Nutrition 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101150051809 KCNH2 gene Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 238000003657 Likelihood-ratio test Methods 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100355655 Mus musculus Eras gene Proteins 0.000 description 1
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010029470 Nodal rhythm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 206010058156 Reperfusion arrhythmia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101150052594 SLC2A3 gene Proteins 0.000 description 1
- 108700032475 Sex-Determining Region Y Proteins 0.000 description 1
- 102100022978 Sex-determining region Y protein Human genes 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108010048992 Transcription Factor 4 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
- 101000929049 Xenopus tropicalis Derriere protein Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 210000003663 amniotic stem cell Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 230000008209 cardiovascular development Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000009744 cell cycle exit Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960001987 dantrolene Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229940049268 euthasol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 239000006055 grower diet Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 102000050201 human TNNT2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000034184 interaction with host Effects 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- QOSWSNDWUATJBJ-UHFFFAOYSA-N n,n'-diphenyloctanediamide Chemical compound C=1C=CC=CC=1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 QOSWSNDWUATJBJ-UHFFFAOYSA-N 0.000 description 1
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004991 placental stem cell Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972330P | 2020-02-10 | 2020-02-10 | |
| PCT/US2021/017220 WO2021163037A1 (en) | 2020-02-10 | 2021-02-09 | Methods of treating and preventing engraftment arrhythmias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295236A true IL295236A (en) | 2022-10-01 |
Family
ID=77291628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295236A IL295236A (en) | 2020-02-10 | 2021-02-09 | Methods of treating and preventing engraftment arrhythmias |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230077983A1 (enExample) |
| EP (1) | EP4103206A4 (enExample) |
| JP (1) | JP2023512843A (enExample) |
| KR (1) | KR20220140532A (enExample) |
| CN (1) | CN115484966A (enExample) |
| AU (1) | AU2021218653A1 (enExample) |
| BR (1) | BR112022015768A2 (enExample) |
| CA (1) | CA3166678A1 (enExample) |
| IL (1) | IL295236A (enExample) |
| MX (1) | MX2022009807A (enExample) |
| WO (1) | WO2021163037A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020245409A1 (en) * | 2019-06-06 | 2020-12-10 | Novo Nordisk A/S | Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof |
| US20230250393A1 (en) * | 2022-02-09 | 2023-08-10 | University Of Washington | Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia |
| US20250101382A1 (en) * | 2022-03-11 | 2025-03-27 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| WO2024073499A2 (en) * | 2022-09-28 | 2024-04-04 | Bluerock Therapeutics Lp | Compositions and methods for treating graft-related arrhythmia |
| WO2025137525A1 (en) * | 2023-12-22 | 2025-06-26 | Bluerock Therapeutics Lp | Molecular identification of cardiomyocytes for cardiac cell therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG192305A1 (en) * | 2012-01-20 | 2013-08-30 | Singapore Health Serv Pte Ltd | Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof in screening for agents |
| EP2833930B1 (en) * | 2012-04-04 | 2018-05-30 | University of Washington through its Center for Commercialization | Systems and method for engineering muscle tissue |
| US9855317B2 (en) * | 2015-04-27 | 2018-01-02 | Reflex Medical, Inc. | Systems and methods for sympathetic cardiopulmonary neuromodulation |
| JP7333271B2 (ja) * | 2017-03-15 | 2023-08-24 | ユニヴァーシティ オブ ワシントン | 心筋細胞の成熟および生着を増強するための方法および組成物 |
| WO2020245409A1 (en) * | 2019-06-06 | 2020-12-10 | Novo Nordisk A/S | Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof |
-
2021
- 2021-02-09 JP JP2022548412A patent/JP2023512843A/ja active Pending
- 2021-02-09 BR BR112022015768A patent/BR112022015768A2/pt not_active Application Discontinuation
- 2021-02-09 WO PCT/US2021/017220 patent/WO2021163037A1/en not_active Ceased
- 2021-02-09 KR KR1020227029054A patent/KR20220140532A/ko not_active Withdrawn
- 2021-02-09 CA CA3166678A patent/CA3166678A1/en active Pending
- 2021-02-09 EP EP21753964.2A patent/EP4103206A4/en active Pending
- 2021-02-09 MX MX2022009807A patent/MX2022009807A/es unknown
- 2021-02-09 CN CN202180027573.1A patent/CN115484966A/zh active Pending
- 2021-02-09 US US17/798,127 patent/US20230077983A1/en active Pending
- 2021-02-09 IL IL295236A patent/IL295236A/en unknown
- 2021-02-09 AU AU2021218653A patent/AU2021218653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103206A1 (en) | 2022-12-21 |
| CN115484966A (zh) | 2022-12-16 |
| JP2023512843A (ja) | 2023-03-29 |
| MX2022009807A (es) | 2022-11-10 |
| AU2021218653A1 (en) | 2022-09-01 |
| BR112022015768A2 (pt) | 2022-11-22 |
| US20230077983A1 (en) | 2023-03-16 |
| KR20220140532A (ko) | 2022-10-18 |
| EP4103206A4 (en) | 2024-03-13 |
| CA3166678A1 (en) | 2021-08-19 |
| WO2021163037A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230077983A1 (en) | Methods of treating and preventing engraftment arrhythmias | |
| Biressi et al. | Stem cell therapy for muscular dystrophies | |
| Manole et al. | Experimental acute myocardial infarction: telocytes involvement in neo‐angiogenesis | |
| Dubois et al. | Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction | |
| EP3556378A1 (en) | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure | |
| JP7091427B2 (ja) | 心不全の治療方法 | |
| IL223453A (en) | Use of 1-tgfb, 4bmp, a- thrombin cardiotropin and cardiogenol c in the treatment of ischemic cardiac therapy, myocardial infarction, or heart failure | |
| WO2012030919A2 (en) | Composition and method for muscle repair and regeneration | |
| WO2018026766A1 (en) | Compositions and methods for treating cardiac injury | |
| Dong et al. | Therapeutic mitochondrial transfer via mesenchymal stem cell-derived microvesicles for macrophage modulation in myocardial infarction complicated by diabetes | |
| Li et al. | Enhanced human adipose‐derived stem cells with VEGFA and bFGF mRNA promote stable vascular regeneration and improve cardiac function following myocardial infarction | |
| US20120020925A1 (en) | Therapeutic Use of Specialized Endothelial Progenitor Cells | |
| US8889122B2 (en) | Cellular cardiomyoplasty as supportive therapy in patients with heart disease | |
| JP2024514215A (ja) | 間葉系幹細胞および血管内皮前駆細胞を有効性分として含む、閉鎖性血管疾患またはその合併症予防または治療用組成物 | |
| US20230250393A1 (en) | Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia | |
| Borenstein et al. | Non-cultured cell transplantation in an ovine model of non-ischemic heart failure | |
| Ovokaitys et al. | Intravenous SONG-modulated laser-activated allogeneic cord blood mesenchymal stem cells for the treatment of endstage heart failure: a preliminary clinical study | |
| Zhang et al. | Management of Engraftment Arrhythmias Associated with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Transplantation | |
| Molino | Beta-3 Adrenoceptor (β3-AR) agonism is a promising strategy against bronchopulmonary dysplasia | |
| Rodrigo | Intramyocardial bone marrow cell injection for ischemic heart disease: efficacy | |
| Gavira-Gómez et al. | A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarction | |
| Ramshorst | Intramyocardial bone marrow cell injection: clinical and functional effects in ischemic heart disease | |
| Taylor et al. | Cell transplantation for cardiovascular repair | |
| Murrow et al. | Cell therapy for cardiovascular disease | |
| Sherman et al. | Burning questions in heart failure management: why do surgeons and interventional cardiologists talk of regenerative cell therapy? |